Circio Holding Asa · OSL:CRNA
Circio Holding Asa — Targovax — Q3 2022 Earnings Presentation
15 slides from Circio Holding Asa's earnings presentation, Nov 3, 2022
Slide 1: Targovax 3Q 2022 presentation
WT ° targovax 3Q 2022 presentation 3 November 2022
Slide 2: Forward-looking statements
This report contains certain forward-looking statements based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on the results of operations and the financial condition of Targovax and the Targovax Gr
Slide 3: Product candidates and milestones
Preclinical Clinical Product candidate Discovery IND- Phase 1 Phase 2 Phase 3 / Milestones enabling pivotal PD-1 Resistant Melanoma 1H 2023 Re-challenge combination w/anti PD-1 Initiation of phase 2 trial (USA) ONCOS-102 Mesothelioma 1H 2023 Combination w/Standard-of-Care (SoC) Publication in oncolo
Slide 4: Melanoma phase 2 trial protocol approved by the FDA
Melanoma phase 2 trial protocol approved by the FDA Trial preparations are on track, Principal Investigator identified Melanoma phase 1 data selected for oral presentation at SITC 2022 and published in high-impact oncology journal Regulatory and ethics approvals in place for both planned academic in
Slide 5: Financial results by quarter (NOK m)
NOK m 3Q21 4Q21 1Q22 2Q22 3Q22 Total revenue 0 0 0 0 0 R&D expenses1 -10 -10 .-9 -14 -8 Payroll and related expenses -11 -13 -16 -14 -10 Other operation expenses2 -2 -2 -3 -3 -2 Total operating expenses -23 -26 -29 -31 -20 -20 Operation loss -23 -26 -29 -31 -20 Net financial items -1 -1 -1 2 0 Loss
Slide 6: Key figures and shareholder base
Key figures Shareholder base - 30 -3 Estimated ownership1 Net cash Shareholder Shares million Ownership flow in 3Q NOK million USD million HealthCap 12.4 6.6 % Avanza Bank AB (nom.) 79.4 3.9 % Goldman Sachs Int. (nom.) 5.2 2.8 % Cash at end of 3Q 96 9.6 Nordnet Bank AB (nom.) Bækkelaget Holding AS 4
Slide 7: The circRNA discoverers work for Targovax
The circRNA discoverers work for Targovax Dr Thomas Hansen Dr Erik D Wiklund 7
Slide 8: circRNA provides a toolbox to take cancer immunotherapy to the next level
circRNA provides a toolbox to take cancer immunotherapy to the next level . ais O Maximize payload expression Extra-cellular trafficking Ob 2D Circular RNA is resistant to exonuclease degradation, leading to vastly increased half-life oo > i Onco-microRNA sponging Immune response booster O A
Slide 9: Highly versatile – Multi-modal MoA – Excellent stability
2022 objectives for the Targovax circRNA program: o Establish technical proof-of- concept (PoC) for circRNA Circular vector approach RNA o Explore and validate advantages of circRNA vs. Gene therapy / Onco-microRNA sponge mRNA delivery protein translation o Optimize vector expression Encode tumor Im
Slide 10: circRNA design superior to mRNA
circRNA payload, protein expression circRNA generation, RNA expression ICOS-L ICOS-L RNA Expresion Protein 10 4 10 Superior protein 8 8 output vs. mRNA 3 achieved even at RNA amount /Beta-actin /GAPDH 6 6 half the RNA 2 amount 4 circRNA payload 4 1 2 2 control 0 0 0 3 V 3 V r VB C ar VB inea C EM iL
Slide 11: Enhanced intra-cellular stability
Enhanced Does not Suitable Delivery Existing Delivery intra-cellular require vaccination to solid GMP manu- to liver stability packaging platform tumors facturing Targovax circRNA vector approach Synthetic circRNA Synthetic mRNA o Targovax has only approach with ability to deliver to solid tumors o
Slide 12: Approach: Oncology, vaccines, enzyme replacement
Approach 1 o Activate validated immuno-stimulatory targets that face Core initial Oncology systemic toxicity issues focus for Solid tumors o Modulate key cancer signalling and metabolic pathways in-house o Immunize against tumor neoantigens development 2 Vaccines o Enhance potency, durability and lo
Slide 13: Technical proof-of-concept achieved for circRNA
✓ Technical proof-of-concept for vector system demonstrating efficient circRNA expression in vitro ✓ Efficient approach for circRNA generation identified ✓ Superior circRNA structural design demonstrating enhanced protein output compared to mRNA 13
Slide 14: World-leading circRNA experts in-house
World-leading circRNA experts in-house with deep technical experience Led by circRNA pionéer Dr. Thomas Hansen Unique vector system for circRNA delivery to solid tumors Technical PoC established, vector turns cancer cells into circRNA factory GMP manufacturing process scale-up ongoing using commerci
Slide 15: 3Q webcast: 3 November 2022
ee .e) targovax 3Q webcast: 3° November 2022, at 10:00 CET Click here